What it's for (Indications)
- Aceclofenac + Olopatadine ophthalmic solution is indicated for the treatment of various ocular conditions characterized by allergic inflammation, itching, and pain.
- Specifically, it is prescribed for the relief of signs and symptoms of seasonal allergic conjunctivitis, where both an anti-inflammatory and an antihistaminic effect are desired.
- This combination addresses the discomfort and redness associated with ocular allergies by targeting both the histamine-mediated immediate hypersensitivity reactions and the subsequent inflammatory cascade.
- It is particularly useful when significant inflammation or pain accompanies the allergic response, offering comprehensive symptomatic relief for patients suffering from moderate to severe ocular allergy manifestations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for Aceclofenac + Olopatadine ophthalmic solution typically involves instilling one drop into the affected eye(s) two times daily, usually at an interval of 8-12 hours. Patients should be instructed to shake the bottle well before each use to ensure uniform suspension of the active ingredients. It is crucial to avoid touching the dropper tip to any surface, including the eye or fingers, to prevent contamination of the solution. If more than one topical ophthalmic medication is being used, a waiting period of at least five to ten minutes between applications is generally recommended to prevent washout of the first medication. The duration of treatment should be determined by the treating ophthalmologist based on the patient's clinical response and the nature of the condition, and it should not exceed the prescribed period. |
Safety & Warnings
Common Side Effects
- As with any ophthalmic medication, Aceclofenac + Olopatadine ophthalmic solution may cause certain side effects, though not everyone experiences them.
- The most commonly reported ocular adverse reactions include transient stinging or burning upon instillation, ocular irritation, blurred vision, foreign body sensation, and dry eye.
- Other less frequent ocular effects might include conjunctival hyperemia, keratitis, and photophobia.
- Due to the aceclofenac component, there is a theoretical risk of corneal adverse events such as corneal thinning, erosions, or perforations, particularly in patients with pre-existing corneal disease or those undergoing repeated topical NSAID exposure.
- Systemic absorption of ophthalmic medications is generally low, but potential systemic effects from aceclofenac could include headache, dizziness, or gastrointestinal discomfort, while olopatadine might rarely lead to headache, asthenia, or taste perversion.
- Patients should report any persistent or worsening side effects to their healthcare provider promptly.
- Allergic reactions, though rare, could manifest as rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, or trouble breathing, requiring immediate medical attention.
Serious Warnings
- Black Box Warning: Serious Ocular Adverse Events Associated with Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Topical ophthalmic NSAIDs, including aceclofenac, have been associated with a risk of serious and potentially sight-threatening corneal adverse events. These include, but are not limited to, keratitis, corneal erosions, corneal ulcerations, and in rare cases, corneal perforation. These events can occur with prolonged use, in patients with pre-existing ocular surface disease (e.g., dry eye syndrome, diabetes, rheumatoid arthritis), in those undergoing complicated ocular surgery, or after repeated ocular surgeries within a short period. Patients with corneal denervation or epithelial defects may also be at increased risk. It is imperative to monitor patients closely for any signs of corneal compromise or toxicity. Treatment with this ophthalmic solution should be immediately discontinued if there is evidence of corneal epithelial breakdown or significant ocular irritation. While systemic NSAID black box warnings for cardiovascular and gastrointestinal risks are generally not applicable to topical ophthalmic preparations due to minimal systemic absorption, the significant localized ocular risks necessitate this prominent safety warning.
- This ophthalmic solution should be used with caution and under strict medical supervision.
- Patients with a known hypersensitivity to aceclofenac, olopatadine, or any component of the formulation, or to other non-steroidal anti-inflammatory drugs (NSAIDs) should avoid its use.
- NSAIDs, including aceclofenac, may slow or delay healing and may also increase the risk of corneal adverse events, especially in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, or rheumatoid arthritis.
- Contact lens wearers should remove their lenses prior to instillation and wait at least 15 minutes after administration before reinserting them, as preservatives in the solution can be absorbed by soft contact lenses.
- Pregnancy and lactation require careful consideration; use only if the potential benefit justifies the potential risk to the fetus or infant, and consultation with a healthcare professional is essential.
- Patients should be advised against operating machinery or driving if they experience transient blurred vision after instillation.
- Persistent ocular irritation, pain, redness, or changes in vision warrant immediate medical evaluation.
How it Works (Mechanism of Action)
The therapeutic efficacy of Aceclofenac + Olopatadine ophthalmic solution is derived from the distinct yet complementary mechanisms of its two active components. Aceclofenac, a potent non-steroidal anti-inflammatory drug (NSAID), exerts its action by inhibiting the enzyme cyclooxygenase (COX), primarily COX-2, which is responsible for the synthesis of prostaglandins. Prostaglandins are key mediators in the inflammatory response, causing pain, vasodilation, and increased vascular permeability. By reducing prostaglandin production, aceclofenac effectively diminishes ocular inflammation, swelling, and pain associated with allergic and inflammatory conditions. Olopatadine, on the other hand, functions primarily as a selective histamine H1-receptor antagonist. It competitively blocks histamine from binding to H1-receptors on conjunctival cells, thereby preventing the immediate hypersensitivity reactions such as itching, redness, and edema that are characteristic of allergic conjunctivitis. Furthermore, olopatadine possesses mast cell stabilizing properties, inhibiting the release of inflammatory mediators from mast cells, including histamine and leukotrienes, following allergen exposure. This dual mechanism provides comprehensive relief by tackling both the acute allergic symptoms and the underlying inflammatory process.
Commercial Brands (Alternatives)
No other brands found for this formula.